BriaCell Therapeutics Corp. (BCTXW)
USD 0.1
(-1.67%)
USD 0.1
(-1.67%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -4.79 Million USD | 79.41% |
| 2023 | -23.27 Million USD | -52.22% |
| 2022 | -15.28 Million USD | -119.24% |
| 2021 | -6.97 Million USD | -93.31% |
| 2020 | -3.6 Million CAD | 23.77% |
| 2019 | -4.73 Million CAD | -23.89% |
| 2018 | -3.81 Million CAD | 0.0% |
| 2017 | - USD | 100.0% |
| 2016 | -1.66 Million CAD | -15.71% |
| 2015 | -1.44 Million CAD | -229.42% |
| 2014 | -437.27 Thousand CAD | -3.07% |
| 2013 | -424.25 Thousand CAD | 64.6% |
| 2012 | -1.19 Million CAD | -13.79% |
| 2011 | -1.05 Million CAD | -224.5% |
| 2010 | -324.56 Thousand CAD | -38.78% |
| 2009 | -233.87 Thousand CAD | -104.93% |
| 2008 | -114.12 Thousand CAD | 11.57% |
| 2007 | -129.05 Thousand CAD | -1404.03% |
| 2006 | -8580.77 CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -9.22 Million USD | 6.1% |
| 2024 Q4 | -5.76 Million USD | 37.51% |
| 2024 Q1 | -8.5 Million USD | -10.35% |
| 2024 Q2 | -9.82 Million USD | -15.6% |
| 2023 Q4 | -7.7 Million USD | -35.74% |
| 2023 FY | -23.27 Million USD | -52.22% |
| 2023 Q3 | -5.67 Million USD | -26.54% |
| 2023 Q2 | -4.48 Million USD | 20.97% |
| 2023 Q1 | -5.67 Million USD | -280.24% |
| 2022 Q2 | 2.19 Million USD | 146.77% |
| 2022 Q3 | 2.3 Million USD | 4.71% |
| 2022 Q1 | 891.03 Thousand USD | -14.24% |
| 2022 FY | -15.28 Million USD | -119.24% |
| 2022 Q4 | 3.14 Million USD | 36.81% |
| 2021 Q3 | 2.39 Million CAD | 1229.99% |
| 2021 FY | -6.97 Million USD | -93.31% |
| 2021 Q4 | 1.03 Million USD | -56.61% |
| 2021 Q2 | 180.05 Thousand CAD | -23.02% |
| 2021 Q1 | 233.91 Thousand CAD | 12.96% |
| 2020 Q3 | 298.2 Thousand CAD | -40.53% |
| 2020 Q1 | 416.53 Thousand CAD | 31.49% |
| 2020 FY | -3.6 Million CAD | 23.77% |
| 2020 Q4 | 207.07 Thousand CAD | -30.56% |
| 2020 Q2 | 501.41 Thousand CAD | 20.38% |
| 2019 Q1 | -980.12 Thousand CAD | 32.0% |
| 2019 FY | -4.73 Million CAD | -23.89% |
| 2019 Q4 | 316.77 Thousand CAD | 9.36% |
| 2019 Q3 | 289.65 Thousand CAD | 121.28% |
| 2019 Q2 | -1.36 Million CAD | -38.89% |
| 2018 Q2 | -802.04 Thousand CAD | -59.44% |
| 2018 Q1 | -503.02 Thousand CAD | 53.24% |
| 2018 FY | -3.81 Million CAD | 0.0% |
| 2018 Q4 | -1.44 Million CAD | -29.92% |
| 2018 Q3 | -1.1 Million CAD | -38.32% |
| 2017 Q2 | -338.08 Thousand CAD | -4.02% |
| 2017 FY | - USD | 100.0% |
| 2017 Q1 | -325.02 Thousand CAD | -58.06% |
| 2017 Q4 | -1.07 Million CAD | -24.79% |
| 2017 Q3 | -862.09 Thousand CAD | -155.0% |
| 2016 FY | -1.66 Million CAD | -15.71% |
| 2016 Q3 | -272.51 Thousand CAD | 64.85% |
| 2016 Q4 | -205.62 Thousand CAD | 24.54% |
| 2016 Q2 | -775.31 Thousand CAD | -148.13% |
| 2016 Q1 | -312.45 Thousand CAD | -4.48% |
| 2015 Q2 | -664.89 Thousand CAD | -457.88% |
| 2015 FY | -1.44 Million CAD | -229.42% |
| 2015 Q4 | -299.06 Thousand CAD | 22.56% |
| 2015 Q1 | -119.18 Thousand CAD | -101.69% |
| 2015 Q3 | -386.21 Thousand CAD | 41.91% |
| 2014 Q2 | -83.1 Thousand CAD | 0.72% |
| 2014 Q1 | -83.7 Thousand CAD | 9.33% |
| 2014 Q3 | 341.24 Thousand CAD | 510.62% |
| 2014 Q4 | 7.03 Million CAD | 1960.96% |
| 2014 FY | -437.27 Thousand CAD | -3.07% |
| 2013 Q1 | -106.42 Thousand CAD | -218.63% |
| 2013 FY | -424.25 Thousand CAD | 64.6% |
| 2013 Q4 | -92.32 Thousand CAD | 22.37% |
| 2013 Q2 | -108.88 Thousand CAD | -2.31% |
| 2013 Q3 | -118.92 Thousand CAD | -9.22% |
| 2012 Q2 | -141.74 Thousand CAD | 5.41% |
| 2012 FY | -1.19 Million CAD | -13.79% |
| 2012 Q1 | -149.84 Thousand CAD | 70.36% |
| 2012 Q4 | 89.7 Thousand CAD | -34.5% |
| 2012 Q3 | 136.95 Thousand CAD | 196.63% |
| 2011 FY | -1.05 Million CAD | -224.5% |
| 2011 Q2 | -184.95 Thousand CAD | -71.55% |
| 2011 Q1 | -107.81 Thousand CAD | -135.17% |
| 2011 Q3 | -235.27 Thousand CAD | -27.21% |
| 2011 Q4 | -505.6 Thousand CAD | -114.9% |
| 2010 Q2 | -92.97 Thousand CAD | -63.05% |
| 2010 Q1 | -57.02 Thousand CAD | 59.41% |
| 2010 Q3 | 110.44 Thousand CAD | 218.78% |
| 2010 Q4 | 306.53 Thousand CAD | 177.55% |
| 2010 FY | -324.56 Thousand CAD | -38.78% |
| 2009 Q4 | -140.48 Thousand CAD | -1473.14% |
| 2009 Q3 | -8929.93 CAD | 73.8% |
| 2009 FY | -233.87 Thousand CAD | -104.93% |
| 2009 Q2 | -34.08 Thousand CAD | 34.65% |
| 2009 Q1 | -52.16 Thousand CAD | 7.93% |
| 2008 Q3 | -28.32 Thousand CAD | -45.0% |
| 2008 Q1 | -10.3 Thousand CAD | 73.83% |
| 2008 Q2 | -19.53 Thousand CAD | -89.61% |
| 2008 FY | -114.12 Thousand CAD | 11.57% |
| 2008 Q4 | -56.66 Thousand CAD | -100.06% |
| 2007 Q4 | -39.36 Thousand CAD | -202.89% |
| 2007 Q2 | -44.91 Thousand CAD | -57.64% |
| 2007 Q3 | -12.99 Thousand CAD | 71.07% |
| 2007 FY | -129.05 Thousand CAD | -1404.03% |
| 2007 Q1 | -28.49 Thousand CAD | 0.0% |
| 2006 FY | -8580.77 CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -237.2 Million USD | 97.98% |
| Alkermes plc | 414.12 Million USD | 101.157% |
| Agenus Inc. | -159.54 Million USD | 96.997% |
| Aptorum Group Limited | -10.52 Million USD | 54.468% |
| Ardelyx, Inc. | -63.27 Million USD | 92.428% |
| Dyadic International, Inc. | -8.22 Million USD | 41.779% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | -301.969% |
| Lantern Pharma Inc. | -17.87 Million USD | 73.198% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | 76.15% |
| Novavax, Inc. | -566.51 Million USD | 99.154% |
| Janux Therapeutics, Inc. | -72.97 Million USD | 93.434% |
| Pyxis Oncology, Inc. | -82.19 Million USD | 94.171% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | 75.325% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | 54.639% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | 90.981% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 98.741% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 80.287% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | 87.347% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 96.285% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 94.29% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 72.681% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | 89.113% |
| Clearside Biomedical, Inc. | -24.84 Million USD | 80.714% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 96.554% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 98.302% |
| AlloVir, Inc. | -181.33 Million USD | 97.358% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 97.663% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 83.623% |
| Bicycle Therapeutics plc | -189.94 Million USD | 97.477% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 97.211% |
| ChromaDex Corporation | -5.59 Million USD | 14.423% |
| Chimerix, Inc. | -93.06 Million USD | 94.851% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 89.371% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 95.872% |
| CRISPR Therapeutics AG | -222.53 Million USD | 97.847% |
| Precision BioSciences, Inc. | -43.73 Million USD | 89.045% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 97.485% |
| Fortress Biotech, Inc. | -142.34 Million USD | 96.634% |
| Fortress Biotech, Inc. | -142.34 Million USD | 96.634% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 95.095% |
| ImmuCell Corporation | -5.74 Million USD | 16.642% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 96.436% |
| Immix Biopharma, Inc. | -16.14 Million USD | 70.315% |
| Incyte Corporation | 620.52 Million USD | 100.772% |
| Innoviva, Inc. | 176.7 Million USD | 102.712% |
| IO Biotech, Inc. | -91.44 Million USD | 94.76% |
| Jaguar Health, Inc. | -34.29 Million USD | 86.027% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 97.181% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | 140.123% |
| ContextLogic Inc. | -328 Million USD | 98.539% |
| MiMedx Group, Inc. | 37.11 Million USD | 112.909% |
| MEI Pharma, Inc. | 14.54 Million USD | 132.949% |
| NextCure, Inc. | -67.63 Million USD | 92.916% |
| Onconetix, Inc. | -36.03 Million USD | 86.703% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | 88.514% |
| Opthea Limited | -191.84 Million USD | 97.502% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -74.12% |
| Vaxcyte, Inc. | -468.04 Million USD | 98.976% |
| PDS Biotechnology Corporation | -43.04 Million USD | 88.869% |
| Precigen, Inc. | -88.92 Million USD | 94.612% |
| Pharming Group N.V. | -4.87 Million USD | 1.805% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 97.136% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | 83.897% |
| PureTech Health plc | -146.19 Million USD | 96.723% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | 76.617% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 97.966% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 80.287% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 98.251% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | 83.65% |
| Acelyrin, Inc. | -422.06 Million USD | 98.865% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | -37057.722% |
| Summit Therapeutics Inc. | -89.73 Million USD | 94.66% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | 87.072% |
| Senti Biosciences, Inc. | -92.72 Million USD | 94.833% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 95.825% |
| Elevation Oncology, Inc. | -45.44 Million USD | 89.457% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | 86.017% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | -21.548% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | -51.533% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | 85.49% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 43.636% |
| Wave Life Sciences Ltd. | -67.99 Million USD | 92.953% |
| Seer, Inc. | -103.46 Million USD | 95.369% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | 92.714% |
| Aadi Bioscience, Inc. | -71.93 Million USD | 93.339% |
| ESSA Pharma Inc. | -32.13 Million USD | 85.089% |
| GlycoMimetics, Inc. | -39.27 Million USD | 87.8% |
| GT Biopharma, Inc. | -13.57 Million USD | 64.706% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 97.814% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | 89.641% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 105.519% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 91.558% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | 90.697% |
| Alzamend Neuro, Inc. | -9.93 Million USD | 51.785% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 99.05% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | 30.538% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 90.548% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 98.155% |
| Aptose Biosciences Inc. | -52.35 Million USD | 90.848% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | 66.774% |
| Soligenix, Inc. | -7.69 Million USD | 37.757% |
| Century Therapeutics, Inc. | -146.54 Million USD | 96.73% |
| Kura Oncology, Inc. | -165.8 Million USD | 97.11% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 94.873% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | 42.403% |
| Ocean Biomedical, Inc. | -2.48 Million USD | -93.077% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | 26.103% |
| Autolus Therapeutics plc | -195.02 Million USD | 97.543% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 94.34% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | 93.495% |
| Eterna Therapeutics Inc. | -21.13 Million USD | 77.329% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 97.89% |
| GRI Bio, Inc. | -11.38 Million USD | 57.922% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -6.106% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 96.348% |
| IGM Biosciences, Inc. | -263.46 Million USD | 98.181% |
| INmune Bio, Inc. | -29.74 Million USD | 83.889% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 95.668% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 87.416% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 70.015% |
| Entero Therapeutics, Inc. | -15.77 Million USD | 69.618% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | 92.158% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 95.544% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 98.264% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 97.642% |
| Verastem, Inc. | -92.08 Million USD | 94.797% |
| Abeona Therapeutics Inc. | -47.13 Million USD | 89.835% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 97.398% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 95.952% |
| Histogen Inc. | -10.64 Million USD | 54.98% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | 69.031% |
| Surrozen, Inc. | -45.78 Million USD | 89.534% |
| Organovo Holdings, Inc. | -15.08 Million USD | 68.239% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 5.869% |
| Ovid Therapeutics Inc. | -59.28 Million USD | 91.917% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 90.659% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | 81.046% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | 37.226% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 97.203% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | 90.11% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | 93.873% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | 68.52% |
| Apollomics, Inc. | -54.83 Million USD | 91.262% |
| Amarin Corporation plc | -67.58 Million USD | 92.911% |
| Mesoblast Limited | -58.79 Million USD | 91.85% |
| Turnstone Biologics Corp. | -59.03 Million USD | 91.883% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 97.105% |
| Synaptogenix, Inc. | -8.31 Million USD | 42.368% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | 67.15% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 94.774% |
| Monopar Therapeutics Inc. | -8.83 Million USD | 45.744% |
| Exelixis, Inc. | 170.88 Million USD | 102.804% |
| Better Therapeutics, Inc. | -38.26 Million USD | 87.477% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 96.91% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 99.073% |
| NLS Pharmaceutics AG | -11.8 Million USD | 59.419% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | 40.419% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 84.025% |
| Gritstone bio, Inc. | -154.63 Million USD | 96.901% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 93.042% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | 72.017% |
| Avid Bioservices, Inc. | -18.67 Million USD | 74.347% |
| Insmed Incorporated | -709.62 Million USD | 99.325% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | 69.461% |
| MediWound Ltd. | -15.29 Million USD | 68.663% |
| OmniAb, Inc. | -69.41 Million USD | 93.098% |
| Alector, Inc. | -151.74 Million USD | 96.842% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 95.563% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 90.812% |
| Zai Lab Limited | -366.57 Million USD | 98.693% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 98.487% |
| Aura Biosciences, Inc. | -84.99 Million USD | 94.362% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 98.048% |
| Immunic, Inc. | -99.22 Million USD | 95.171% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 96.653% |
| Veracyte, Inc. | -85.79 Million USD | 94.415% |
| InMed Pharmaceuticals Inc. | - USD | Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 98.3% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 66.281% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | 30.437% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | 74.503% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 100.828% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | 81.175% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | 112.349% |
| TG Therapeutics, Inc. | 20.63 Million USD | 123.222% |
| Galecto, Inc. | -39.9 Million USD | 87.993% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 88.612% |
| Fortrea Holdings Inc. | 63.1 Million USD | 107.593% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 96.588% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | 83.408% |
| XBiotech Inc. | -37.51 Million USD | 87.226% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 93.042% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | 92.861% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 95.56% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 81.336% |
| Theravance Biopharma, Inc. | -53.29 Million USD | 91.009% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 99.158% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | 93.896% |
| Vaxxinity, Inc. | -58.28 Million USD | 91.779% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 95.38% |
| Gain Therapeutics, Inc. | -22.25 Million USD | 78.468% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 94.455% |
| NexImmune, Inc. | -29.19 Million USD | 83.587% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | 14.745% |
| Marker Therapeutics, Inc. | -14.58 Million USD | 67.14% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 100.118% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | 81.18% |
| Scopus BioPharma Inc. | -11.71 Million USD | 59.099% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 96.229% |
| Ainos, Inc. | -13.2 Million USD | 63.719% |
| Pluri Inc. | -22.15 Million USD | 78.376% |
| Prothena Corporation plc | -191.03 Million USD | 97.492% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 96.529% |
| Celularity Inc. | -192.28 Million USD | 97.508% |
| Rallybio Corporation | -78.93 Million USD | 93.93% |
| Cue Biopharma, Inc. | -52.14 Million USD | 90.812% |
| MeiraGTx Holdings plc | -137.06 Million USD | 96.504% |
| Omeros Corporation | -164.53 Million USD | 97.088% |
| Humacyte, Inc. | -100.04 Million USD | 95.211% |
| Immunocore Holdings plc | -59.64 Million USD | 91.967% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | 74.183% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | 80.429% |
| Blueprint Medicines Corporation | -486.27 Million USD | 99.015% |
| CalciMedica, Inc. | -21.87 Million USD | 78.096% |
| Cabaletta Bio, Inc. | -74.66 Million USD | 93.582% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 96.356% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 97.203% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 98.534% |
| Pulmatrix, Inc. | -14.74 Million USD | 67.493% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | 86.595% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 94.608% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 99.07% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | 92.907% |
| Cytokinetics, Incorporated | -496.2 Million USD | 99.034% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 86.079% |
| Nutriband Inc. | -4.87 Million USD | 1.652% |
| Protara Therapeutics, Inc. | -43.61 Million USD | 89.014% |
| Vor Biopharma Inc. | -126.03 Million USD | 96.198% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 100.113% |
| Evogene Ltd. | -26.39 Million USD | 81.844% |
| ProKidney Corp. | -151.52 Million USD | 96.838% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 92.575% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | 37.71% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 99.211% |
| CorMedix Inc. | -48.95 Million USD | 90.213% |
| BioLineRx Ltd. | -49.69 Million USD | 90.358% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 95.803% |
| Galectin Therapeutics Inc. | -38.07 Million USD | 87.415% |
| Atai Life Sciences N.V. | -125.47 Million USD | 96.181% |
| Renovaro Biosciences Inc. | -81.63 Million USD | 94.131% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | 94.114% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 98.076% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 84.413% |
| MediciNova, Inc. | -9.9 Million USD | 51.603% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 96.208% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 33.842% |
| GeoVax Labs, Inc. | -26.74 Million USD | 82.083% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 97.933% |
| Biomea Fusion, Inc. | -126.13 Million USD | 96.201% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 98.629% |
| Mereo BioPharma Group plc | -28.41 Million USD | 83.138% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 97.493% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 97.916% |
| Absci Corporation | -115.51 Million USD | 95.852% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 82.631% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 95.755% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 98.021% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | 80.983% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 97.696% |
| Allakos Inc. | -196.05 Million USD | 97.556% |
| Imunon, Inc. | -21.03 Million USD | 77.217% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 95.67% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 104.466% |
| BioAtla, Inc. | -129.68 Million USD | 96.305% |
| NLS Pharmaceutics AG | -11.8 Million USD | 59.419% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 69.757% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 98.538% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | 88.526% |
| XOMA Corporation | -41.84 Million USD | 88.55% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 95.447% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 96.056% |
| aTyr Pharma, Inc. | -54.91 Million USD | 91.275% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 94.519% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 97.228% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 98.117% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | 77.679% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | 41.658% |
| Akari Therapeutics, Plc | -16.8 Million USD | 71.49% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -54083.532% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 101.419% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 26.669% |
| UroGen Pharma Ltd. | -65.53 Million USD | 92.689% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 94.633% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 34.029% |
| Orgenesis Inc. | -53.63 Million USD | 91.067% |
| Entera Bio Ltd. | -8.89 Million USD | 46.109% |
| GH Research PLC | -41.22 Million USD | 88.376% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | 81.362% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | 94.231% |
| Xencor, Inc. | -138.63 Million USD | 96.544% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | 7.045% |
| Replimune Group, Inc. | -234.77 Million USD | 97.959% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | 77.705% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | 65.657% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 26.669% |
| Portage Biotech Inc. | -18.25 Million USD | 73.75% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 33.842% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 95.435% |
| OncoCyte Corporation | -25.13 Million USD | 80.938% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 57.616% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 58.179% |
| Purple Biotech Ltd. | 22.27 Million USD | 121.514% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | 36.216% |
| scPharmaceuticals Inc. | -55.39 Million USD | 91.351% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | 74.645% |
| HilleVax, Inc. | -133.34 Million USD | 96.407% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | 60.233% |
| Tharimmune, Inc. | -9.45 Million USD | 49.325% |
| Genprex, Inc. | -31.07 Million USD | 84.581% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 97.454% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | 84.729% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | -526.335% |
| Virios Therapeutics, Inc. | -5.44 Million USD | 12.033% |
| OKYO Pharma Limited | -15.74 Thousand USD | -30322.528% |
| Savara Inc. | -60 Million USD | 92.015% |
| Curis, Inc. | -48.33 Million USD | 90.086% |
| Daré Bioscience, Inc. | -30.83 Million USD | 84.463% |
| Carmell Therapeutics Corporation | -5.21 Million USD | 8.162% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | 34.156% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | 82.417% |
| BeiGene, Ltd. | -1.2 Billion USD | 99.603% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 75.97% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 99.016% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 94.884% |
| Erasca, Inc. | -141.52 Million USD | 96.614% |
| bluebird bio, Inc. | -244.26 Million USD | 98.038% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -5.843% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 102.464% |
| DBV Technologies S.A. | -76.43 Million USD | 93.731% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -5.843% |
| Moderna, Inc. | -4.23 Billion USD | 99.887% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 88.755% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | 24.662% |
| Molecular Templates, Inc. | -10.46 Million USD | 54.219% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | 92.874% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 98.728% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 96.657% |
| Spruce Biosciences, Inc. | -51.99 Million USD | 90.784% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 96.9% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 97.698% |
| MacroGenics, Inc. | -168.24 Million USD | 97.152% |
| RenovoRx, Inc. | -11.39 Million USD | 57.955% |
| Adicet Bio, Inc. | -152.03 Million USD | 96.849% |
| Prime Medicine, Inc. | -191.29 Million USD | 97.495% |
| Aditxt, Inc. | -26.06 Million USD | 81.615% |
| Adagene Inc. | -23.71 Million USD | 79.8% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 34.454% |
| Quantum-Si incorporated | -111.17 Million USD | 95.69% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | 84.86% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 67.132% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | 103.927% |
| SciSparc Ltd. | -5.77 Million USD | 17.002% |
| Vericel Corporation | -6.46 Million USD | 25.875% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 44.65% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | 79.275% |
| Generation Bio Co. | -138.56 Million USD | 96.542% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 94.229% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 94.458% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 98.013% |
| Invivyd, Inc. | -207.78 Million USD | 97.694% |
| Relay Therapeutics, Inc. | -373 Million USD | 98.715% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | 48.91% |
| Spero Therapeutics, Inc. | 21.48 Million USD | 122.306% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 53.422% |
| 2seventy bio, Inc. | -216.7 Million USD | 97.789% |
| ADMA Biologics, Inc. | 21.63 Million USD | 122.15% |
| Clene Inc. | -40.54 Million USD | 88.181% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | 80.1% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | 91.256% |
| GeoVax Labs, Inc. | -26.74 Million USD | 82.083% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 98.631% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | 86.956% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | 129.803% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 95.38% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 85.908% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 97.186% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 99.3% |
| Evaxion Biotech A/S | -22.19 Million USD | 78.414% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | 94.184% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 97.853% |
| Trevena, Inc. | -35.28 Million USD | 86.422% |
| Surrozen, Inc. | -45.78 Million USD | 89.534% |
| Tyra Biosciences, Inc. | -79.94 Million USD | 94.007% |
| Cingulate Inc. | -22.75 Million USD | 78.947% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | 163.954% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 89.273% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | 41.808% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 95.328% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | 93.47% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | 92.281% |
| Clearmind Medicine Inc. | -8.74 Million USD | 45.186% |
| Kronos Bio, Inc. | -121.83 Million USD | 96.067% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | 93.712% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -63.365% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 95.248% |
| Statera Biopharma, Inc. | -98.34 Million USD | 95.128% |
| ImmunityBio, Inc. | -362.25 Million USD | 98.677% |
| Korro Bio, Inc. | -84.53 Million USD | 94.332% |
| Kineta, Inc. | -15.72 Million USD | 69.526% |
| BioVie Inc. | -32.17 Million USD | 85.11% |
| Codexis, Inc. | -68.06 Million USD | 92.961% |
| Celularity Inc. | -192.28 Million USD | 97.508% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 97.848% |
| Celcuity Inc. | -66.23 Million USD | 92.765% |
| Virax Biolabs Group Limited | -6.49 Million USD | 26.245% |
| Cibus, Inc. | -318.88 Million USD | 98.497% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | 88.857% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 85.842% |
| IN8bio, Inc. | -30.33 Million USD | 84.206% |
| Kodiak Sciences Inc. | -277.32 Million USD | 98.272% |
| Annexon, Inc. | -143.72 Million USD | 96.666% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 96.129% |
| Assembly Biosciences, Inc. | -64.64 Million USD | 92.588% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | 79.562% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 98.645% |
| Eyenovia, Inc. | -25.4 Million USD | 81.141% |
| Puma Biotechnology, Inc. | 32.64 Million USD | 114.68% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 13.854% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | 93.945% |
| Arcellx, Inc. | -89.88 Million USD | 94.669% |
| Cardiff Oncology, Inc. | -45.41 Million USD | 89.449% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 96.508% |
| Regulus Therapeutics Inc. | -31.1 Million USD | 84.598% |
| Moolec Science SA | -6.65 Million USD | 27.989% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | 92.163% |
| Geron Corporation | -193.94 Million USD | 97.529% |
| LAVA Therapeutics N.V. | -43.25 Million USD | 88.922% |
| Royalty Pharma plc | 1.49 Billion USD | 100.321% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 97.081% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 48.633% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | 78.116% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 97.197% |
| Humacyte, Inc. | -100.04 Million USD | 95.211% |
| Structure Therapeutics Inc. | -102.77 Million USD | 95.338% |
| 89bio, Inc. | -151.2 Million USD | 96.831% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | 94.021% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | 67.046% |
| Genelux Corporation | -24.16 Million USD | 80.172% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | 85.875% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 97.21% |
| Notable Labs, Ltd. | -14.65 Million USD | 67.309% |
| Liquidia Corporation | -73.38 Million USD | 93.471% |
| Mustang Bio, Inc. | -50.72 Million USD | 90.554% |
| Immunovant, Inc. | -282.7 Million USD | 98.305% |
| Quantum-Si incorporated | -111.17 Million USD | 95.69% |
| Arbutus Biopharma Corporation | -78.1 Million USD | 93.865% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | 77.47% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 95.303% |
| Acasti Pharma Inc. | -11.31 Million USD | 57.643% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | 79.096% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 70.015% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 97.762% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | -30.591% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 69.838% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | 83.567% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | 88.422% |
| PepGen Inc. | -84.76 Million USD | 94.347% |
| Moleculin Biotech, Inc. | -29.63 Million USD | 83.83% |
| United Therapeutics Corporation | 1.18 Billion USD | 100.404% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 79.074% |
| Solid Biosciences Inc. | -104.31 Million USD | 95.407% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | 85.395% |
| Immuneering Corporation | -58.41 Million USD | 91.797% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 5.869% |
| Silo Pharma, Inc. | -3.85 Million USD | -24.273% |
| Belite Bio, Inc | -31.66 Million USD | 84.87% |
| XOMA Corporation | -41.84 Million USD | 88.55% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | 92.904% |
| Bionomics Limited | -17.89 Billion USD | 99.973% |
| Apogee Therapeutics, Inc. | -93 Million USD | 94.848% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 113.429% |
| uniQure N.V. | -282.87 Million USD | 98.306% |
| Cassava Sciences, Inc. | -105.95 Million USD | 95.478% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 34.454% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 96.3% |
| Forte Biosciences, Inc. | -32.48 Million USD | 85.251% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | 42.332% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | 83.7% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 13.854% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 66.281% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | 46.097% |
| Altimmune, Inc. | -95.92 Million USD | 95.005% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 93.48% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 113.429% |
| Compugen Ltd. | -12.99 Million USD | 63.12% |
| Peak Bio, Inc. | -1356.23 USD | -353193.026% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | 90.341% |
| Benitec Biopharma Inc. | -22.49 Million USD | 78.695% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 98.023% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | 83.892% |
| Zura Bio Limited | -62.63 Million USD | 92.351% |
| PolyPid Ltd. | -22.86 Million USD | 79.046% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | 70.561% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | 83.892% |
| Instil Bio, Inc. | -159.16 Million USD | 96.99% |
| argenx SE | -425.04 Million USD | 98.873% |
| Immunome, Inc. | -109.53 Million USD | 95.625% |
| Compass Therapeutics, Inc. | -50.36 Million USD | 90.486% |
| Verona Pharma plc | -67.83 Million USD | 92.936% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | 81.614% |
| Shattuck Labs, Inc. | -91.95 Million USD | 94.789% |
| CervoMed Inc. | -7.81 Million USD | 38.672% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | 93.446% |
| Plus Therapeutics, Inc. | -13.32 Million USD | 64.031% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 90.054% |
| Moolec Science SA | -6.65 Million USD | 27.989% |
| Enveric Biosciences, Inc. | -16.44 Million USD | 70.87% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 96.457% |
| AnaptysBio, Inc. | -164.41 Million USD | 97.086% |
| Design Therapeutics, Inc. | -78.19 Million USD | 93.872% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 94.495% |
| NeurAxis, Inc. | -6.66 Million USD | 28.105% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | 88.169% |
| Lumos Pharma, Inc. | -36.61 Million USD | 86.914% |
| Achilles Therapeutics plc | -75.25 Million USD | 93.633% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | 81.614% |
| 180 Life Sciences Corp. | -13.47 Million USD | 64.448% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | 192.924% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -63.365% |
| Nutriband Inc. | -4.87 Million USD | 1.652% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 95.675% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | 91.359% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | 90.575% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | 92.751% |
| MoonLake Immunotherapeutics | -54.12 Million USD | 91.147% |
| Palisade Bio, Inc. | -13.07 Million USD | 63.34% |
| Tourmaline Bio, Inc. | -45.4 Million USD | 89.448% |
| Beam Therapeutics Inc. | -176.48 Million USD | 97.285% |
| Neurogene Inc. | -55.58 Million USD | 91.38% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 95.61% |
| AEON Biopharma, Inc. | -48.42 Million USD | 90.106% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 95.046% |
| Sesen Bio, Inc. | -25.9 Million USD | 81.507% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 94.264% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | 61.933% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 98.96% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | 93.386% |
| Athira Pharma, Inc. | -125.46 Million USD | 96.181% |
| Vaccinex, Inc. | -22.88 Million USD | 79.063% |
| HCW Biologics Inc. | -25.71 Million USD | 81.369% |
| XOMA Corporation | -41.84 Million USD | 88.55% |
| Nektar Therapeutics | -137.42 Million USD | 96.513% |
| Arvinas, Inc. | -401.5 Million USD | 98.807% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -54083.532% |
| Merus N.V. | -156.54 Million USD | 96.939% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 95.221% |
| Quince Therapeutics, Inc. | -34.62 Million USD | 86.16% |
| Rezolute, Inc. | -70.42 Million USD | 93.196% |
| Clene Inc. | -40.54 Million USD | 88.181% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | 70.745% |
| BeyondSpring Inc. | -23.11 Million USD | 79.27% |
| Synlogic, Inc. | -55.16 Million USD | 91.314% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | 73.275% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 55.733% |
| Peak Bio, Inc. | -1356.23 USD | -353193.026% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | 88.17% |
| Krystal Biotech, Inc. | -109.72 Million USD | 95.633% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 96.301% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 98.603% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | -0.959% |
| MannKind Corporation | 8.67 Million USD | 155.214% |
| Ikena Oncology, Inc. | -75.41 Million USD | 93.647% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | 50.332% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | 92.873% |
| Gossamer Bio, Inc. | -183.75 Million USD | 97.393% |
| CohBar, Inc. | -12.38 Million USD | 61.323% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | 90.554% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 82.631% |
| Legend Biotech Corporation | -439.48 Million USD | 98.91% |
| Mural Oncology plc | -194.63 Million USD | 97.538% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 92.864% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 70.323% |
| Disc Medicine, Inc. | -91.12 Million USD | 94.742% |
| Champions Oncology, Inc. | -7.35 Million USD | 34.863% |
| REGENXBIO Inc. | -268.12 Million USD | 98.213% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 55.296% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 91.406% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | 87.702% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 95.81% |
| Vaxart, Inc. | -83.34 Million USD | 94.251% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | 43.762% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | 88.803% |
| Cellectis S.A. | -106.62 Million USD | 95.506% |
| Longeveron Inc. | -21.02 Million USD | 77.215% |
| Repare Therapeutics Inc. | -116.22 Million USD | 95.877% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 98.211% |
| Inozyme Pharma, Inc. | -75.64 Million USD | 93.666% |
| Revolution Medicines, Inc. | -487.18 Million USD | 99.016% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | 27.97% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | 89.099% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 93.576% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | 93.119% |
| Anixa Biosciences, Inc. | -11.01 Million USD | 56.485% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 100.111% |
| Denali Therapeutics Inc. | -196.69 Million USD | 97.564% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 44.65% |
| Veru Inc. | -93.78 Million USD | 94.891% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | 79.461% |
| Cingulate Inc. | -22.75 Million USD | 78.947% |
| Passage Bio, Inc. | -108.38 Million USD | 95.579% |
| Context Therapeutics Inc. | -25.07 Million USD | 80.89% |
| Exicure, Inc. | -14.99 Million USD | 68.048% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 97.675% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | 88.198% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | 50.69% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 97.401% |
| Nuvalent, Inc. | -149.49 Million USD | 96.795% |
| ABVC BioPharma, Inc. | -8.21 Million USD | 41.685% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 94.6% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | 76.935% |
| OmniAb, Inc. | -69.41 Million USD | 93.098% |
| Anew Medical, Inc. | -1.3 Million USD | -268.336% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | 62.482% |
| Lipocine Inc. | -17.93 Million USD | 73.278% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | 93.006% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | 93.708% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 87.416% |
| G1 Therapeutics, Inc. | -39.52 Million USD | 87.878% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | 78.594% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 99.174% |
| Ocugen, Inc. | -65.53 Million USD | 92.688% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 94.895% |
| Q32 Bio Inc. | -92.1 Million USD | 94.798% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | 77.651% |
| Alumis Inc. Common Stock | -158.17 Million USD | 96.971% |
| Equillium, Inc. | -14.52 Million USD | 67.005% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | 92.322% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 39.374% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 74.601% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 89.795% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 95.583% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 59.971% |
| Dominari Holdings Inc. | -21.79 Million USD | 78.017% |
| Edesa Biotech, Inc. | -9.22 Million USD | 48.047% |
| vTv Therapeutics Inc. | -25.5 Million USD | 81.211% |
| Bio-Techne Corporation | 206.68 Million USD | 102.318% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 98.776% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | 102.495% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 96.378% |
| Candel Therapeutics, Inc. | -38.39 Million USD | 87.519% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 96.829% |
| Nkarta, Inc. | -131.65 Million USD | 96.36% |
| BioCardia, Inc. | -11.64 Million USD | 58.85% |
| Iterum Therapeutics plc | -47.46 Million USD | 89.906% |